The legal action, spearheaded by Pomerantz LLP, targets the company’s operations during the designated class period. Central to the complaint are findings from a July 29, 2026, Federal Trade Commission filing. Regulators allege the firm promised privacy while secretly funneling medical condition data to third-party platforms. Furthermore, the FTC claims the company deceived customers by charging for prescriptions immediately upon form submission, contradicting promises of a personalized consultation process to determine appropriate treatments.
Hims & Hers Faces Class Action Over Privacy and Billing Practices
A federal lawsuit is challenging the business conduct of Hims & Hers Health, Inc., following allegations that the telehealth company misled users about billing transparency and shared sensitive health data with advertising giants like Meta and Snap without proper consumer consent.
Investors suffered significant financial fallout when the news broke. Hims & Hers stock plummeted $4.32 per share, a 14.73% drop, closing at $25.00 on the day of the FTC announcement. Shareholders who acquired securities during the period now have until November 2, 2026, to petition the court for lead plaintiff status. Pomerantz LLP is currently managing inquiries from affected parties regarding the ongoing securities fraud litigation.
Comments (0)
No comments yet. Be the first!